Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety, tolerability, and effectiveness of a single injection of PTP-001 MOTYS in treating knee osteoarthritis OA in adults aged 40 to 80 years. This Phase 3, multicenter, randomized, double-blind, placebo-controlled trial compares PTP-001 to a placebo over a 52-week period in participants with mild to moderate knee OA confirmed by X-ray and symptoms. The goal is to assess improvements in knee function and pain over time. Participants will be randomly assigned to receive either a single 200 mg injection of PTP-001 or a placebo injection directly into the affected knee on Day 1. The study includes a screening period of up to 28 days before treatment, followed by the injection day and a 12-month follow-up phase to monitor outcomes. At least 260 participants will take part, split evenly between the two groups. Throughout the study, participants will attend scheduled visits for assessments including knee pain and function questionnaires, such as the WOMAC and PGA-OA scores, at 6, 9, and 12 months. Researchers will track improvements in knee symptoms and overall osteoarthritis status, as well as monitor safety and tolerability. Participants are expected to comply with study visits and restrictions, using only acetaminophen as needed for pain relief during the trial.
Actively Recruiting
Seasonal influenza affects about one billion people worldwide each year, with 3 to 5 million cases being severe and causing up to 650,000 deaths annually. Vaccine effectiveness varies widely, often below 50%, and can be as low as 5% in people with weakened immune systems. This study aims to evaluate whether MK-1406 CD388 can help prevent influenza in adolescents and adults who are at increased risk of serious illness due to age, health conditions, or immune system weakness. Participants will receive a single dose of MK-1406 or a placebo through three subcutaneous injections during one study visit. The study is a Phase 3, randomized, double-blind, placebo-controlled trial conducted at multiple centers. It compares the safety, tolerability, and effectiveness of MK-1406 against placebo for preventing influenza in higher-risk individuals. During the study, participants will be monitored for up to approximately 24 weeks to track the occurrence of influenza-like illness, adverse events, and other health outcomes. Blood samples will be collected at specific times to measure drug levels and immune responses. Safety will be closely followed, including monitoring for injection site reactions and treatment-related antibodies. Participants health will be observed throughout the study period ending around 24 weeks post-dose.
Actively Recruiting
Researchers are evaluating the effectiveness, safety, and tolerability of two drug combinations Cabotegravir Ultra Long-Acting CAB ULA plus Rilpivirine Ultra Long-Acting RPV ULA, and Cabotegravir Long-Acting CAB LA plus Rilpivirine Long-Acting RPV LA in adults and adolescents living with HIV who have their virus suppressed through antiretroviral therapy ART. This phase III trial aims to compare these treatments to understand their impact on maintaining viral suppression. Participants receive either the CAB ULA plus RPV ULA combination or the CAB LA plus RPV LA combination. These medications are administered as long-acting injectable drugs. The study uses a randomized, parallel-group design where participants are assigned to one of these two treatment groups to compare outcomes over time. During the trial, participants will be monitored closely with regular assessments including measuring plasma HIV-RNA levels, tracking any virologic failure, and evaluating drug-related adverse events. Laboratory tests will monitor drug concentrations and immune cell counts CD4 cells. The main outcome is the percentage of participants with HIV-RNA levels above 50 copiesmL at month 11. The study follows participants for up to 23 months to assess longer-term effects and safety.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the safety and immune response of different vaccine formulations targeting the Respiratory Syncytial Virus RSV monovalent antigen and the Influenza AH5N1 hemagglutinin subtype 5 H5 antigen in healthy adults aged 18 to 49 years. This phase 1 study aims to understand how well these vaccines work and how safe they are for this age group, with participation durations varying by treatment group and study stage. Participants receive vaccines through intramuscular injections. For certain groups, injections are given on day 1 and day 22 with the H5 Flu vaccines, while others receive a single injection on day 1 with the RSV vaccines. The study is divided into two stages, with Stage 1 lasting approximately 6 to 7 months depending on the arm, and Stage 2 lasting about 7 months for all arms. Vaccines are given according to a randomization schedule across multiple experimental arms. Throughout the study, participants will be monitored closely for side effects such as injection site reactions, systemic symptoms, and any adverse events up to 6 months after vaccination. Researchers will collect blood samples to measure antibody responses before and after vaccination at various time points. The study includes detailed safety assessments, including biological tests and documentation of any serious adverse events or events leading to discontinuation. Participants immune responses to both RSV and Flu H5 antigens will be measured using specific antibody tests over the course of the study.